期刊
PHARMACOGENOMICS
卷 21, 期 5, 页码 337-346出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2019-0186
关键词
liver toxicity; methotrexate; MTHFR; rheumatoid arthritis; transaminases; TYMS and SLCO1B1
资金
- Agnes and Mac Rudberg Foundation
- Swedish Research Council [Medicine 521-20112440, 521-2014-3370, 2018-03307]
- Swedish Heart and Lung Foundation [20120557, 20140291, 20170711]
- Selander's Foundation
- Thureus' Foundation
- Swedish Medical Products Agency
- Vinnova [2018-03307] Funding Source: Vinnova
- Swedish Research Council [2018-03307] Funding Source: Swedish Research Council
Aims: To investigate whether variants of MTHFR, TYMS and SLCO1B1 are associated with ALT elevation in rheumatoid arthritis patients starting methotrexate (MTX). Patients & methods: Clinical and laboratory data were collected from the start of MTX treatment. Genotyping of MTHFR, TYMS and SLCO1B1 was performed. Univariate and multiple logistic regression were used for statistical analysis. Results: 34 out of 369 patients experienced ALT >1.5 x ULN less than 6 months from start. MTHFR A1298C (rs1801131) was nominally associated with an ALT >1.5 x ULN within 6 months after the start of MTX (OR = 1.7 [95% CI: 1.04-2.9]; p = 0.03), but did not pass correction for multiple testing. A multiple model containing MTHFR 1298C and clinical factors predicted the outcome (C-statistic 0.735). TYMS and SLCO1B1 were not associated with the outcome. Conclusions: A model containing MTHFR 1298C and clinical factors might predict risk of early ALT elevation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据